Indeed, from a biological perspective our findings are in line with the expected corticosteroid effects, suggesting that SNPs of the GR gene leading to either hypo- or hypersensitivity to GC, indeed modulate long-term cardiometabolic outcome after treatment of CS. The gene discussed is NR3C1; the disease is Cowden syndrome 1.